Lab tests confirmed metabolites, some of which activated CB1

In vitro human hepatocyte incubation of 5F-MDMB-PINACA, 5F-MDMB-PICA, 5F-EMDB-PICA, 4F-MDMB-BICA, and 4F-MDMB-BINACA and cannabinoid receptor 1 activity profiling of major human metabolites.

Archives of toxicology • • Highly Relevant
🤖

AI Summary

This study asked whether major metabolites of five fluorinated synthetic cannabinoid receptor agonists could be confirmed with reference standards and whether those metabolites activate CB1. Researchers incubated the compounds with human hepatocytes in vitro, identified metabolites using mass spectrometry, and tested parent compounds and metabolites in a recombinant-cell activity assay. This was a laboratory study, not a trial in people.

The researchers confirmed 16 of 20 assessed metabolites. Ten major, rapidly formed metabolites—including hydroxylated products, oxidative defluorination products, and ester-hydrolysis products—showed high to moderate CB1 potency, with reported EC₅₀ values from 96.3 nM to 8.07 μM. Metabolites that had undergone multiple transformations showed little or no receptor activation. These findings can help support synthetic-cannabinoid detection and clarify possible metabolite activity, but the in vitro results cannot establish effects or harms in people; this is an abstract-based summary.

💡 Key Findings

1
Researchers confirmed 16 of 20 assessed metabolites of five fluorinated synthetic cannabinoid agonists using reference standards.
High
95%
2
Ten major, rapidly formed metabolites showed high to moderate CB1 potency in a recombinant-cell assay (EC₅₀ 96.3 nM–8.07 μM).
High
95%
3
Metabolites with multiple biotransformations showed little to no CB1 activation in the assay.
High
95%

📄 Original Abstract

Since their first reported fatalities in 2016, fluorinated MDMB-group synthetic cannabinoid receptor agonists (SCRAs), 5F-MDMB-PINACA, 5F-MDMB-PICA, 5F-EDMB-PICA, 4F-MDMB-BICA, and 4F-MDMB-BINACA, have remained present on illegal drug markets. Detection of SCRAs in clinical and forensic casework relies on metabolite detection, yet confirmation using metabolite reference standards is often lacking. Moreover, limited knowledge is available regarding the metabolites' activity at the cannabinoid 1 receptor (CB1) and their potential contribution to cannabinoid pharmacology and toxicology. Therefore, this work aimed to confirm major metabolites of the five analogue SCRAs using in-house-synthesized reference standards and evaluate their activity at the CB1 receptor. SCRAs (5 µM) were incubated for 3 h with human hepatocytes, and supernatants were analyzed by high-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (HPLC-QToF-MS), and spectra were compared with reference standards. Parent and metabolite activity were measured using an in vitro recombinant cell AequoScreen® assay with a concentration range of 0.0286 nM-60 µM. Sixteen of 20 assessed metabolites were confirmed, including major metabolites such as ester hydrolysis (EH), carboxylic acid formation, combinations with oxidative defluorination (OD). Ten major and rapidly formed metabolites, such as hydroxylated metabolites, OD, and EH, showed high to moderate CB1 potency (EC50 96.3 nM-8.07 µM), whereas metabolites with multiple biotransformations showed little to no activation. Together, this study confirms several major metabolites using reference standards and characterizes their CB1 activity, improving confidence in SCRA detection and providing insight into metabolite contribution to cannabinoid-related activity.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.